GT Biopharma, Inc.
GTBP· Nasdaq
GTBPGT Biopharma, Inc.
Filed Mar 30, 2023 · 10-K · 89 days after period end · 0001493152-23-009812
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | — |
| Net Income | -$5.58M | -$18.02M | -$6.29M | -$1.47M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 30, 2023 · 89 d after period end
